Dissection of functional sites in herpesvirus saimiri complement control protein homolog

Journal of Virology

Volumn 87, Issue 1, 2013, Pages 282-295

  Reza, Malik Johid ^a   Kamble, Ashish ^a   Ahmad, Muzammil ^a   Krishnasastry, Musti V ^a   Sahu, Arvind ^a  

^a NATIONAL CENTRE FOR CELL SCIENCE   (India)

Author keywords

[No Author keywords available]

Indexed keywords

CLASSICAL COMPLEMENT PATHWAY C3 C5 CONVERTASE; COMPLEMENT COMPONENT C3B; COMPLEMENT COMPONENT C4B; COMPLEMENT CONTROL PROTEIN HOMOLOG; UNCLASSIFIED DRUG; VIRUS PROTEIN;

AMINO ACID SUBSTITUTION; ARTICLE; BINDING SITE; ENZYME ACTIVITY; GAIN OF FUNCTION MUTATION; HERPES VIRUS SAIMIRI; HUMAN; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; SIGNAL TRANSDUCTION;

AMINO ACID SUBSTITUTION; COMPLEMENT FACTOR I; DNA MUTATIONAL ANALYSIS; HERPESVIRUS 2, SAIMIRIINE; MUTANT PROTEINS; PROTEIN BINDING; VIRAL PROTEINS;

SAIMIRIINE HERPESVIRUS 2;

EID: 84871979451     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.01867-12     Document Type: Article

References (64)

1. Judson KA, Lubinski JM, Jiang M, Chang Y, Eisenberg RJ, Cohen GH, Friedman HM. 2003. Blocking immune evasion as a novel approach for prevention and treatment of herpes simplex virus infection. J. Virol. 77: 12639-12645.
2. Lachmann PJ. 2002. Microbial subversion of the immune response. Proc. Natl. Acad. Sci. U. S. A. 99:8461-8462.
3. Mullick J, Kadam A, Sahu A. 2003. Herpes and pox viral complement control proteins: 'the mask of self.' Trends Immunol. 24:500-507.
4. Carroll MC. 2004. The complement system in regulation of adaptive immunity. Nat. Immunol. 5:981-986.
5. Dunkelberger JR, Song WC. 2010. Complement and its role in innate and adaptive immune responses. Cell Res. 20:34-50.
6. Pyaram K, Yadav VN, Reza MJ, Sahu A. 2010. Virus-complement interactions: an assiduous struggle for dominance. Future Virol. 5:709-730.
7. Finlay BB, McFadden G. 2006. Anti-immunology: evasion of the host immune system by bacterial and viral pathogens. Cell 124:767-782.
8. Lambris JD, Ricklin D, Geisbrecht BV. 2008. Complement evasion by human pathogens. Nat. Rev. Microbiol. 6:132-142.
9. Liang CY, Lee JS, Jung JU. 2008. Immune evasion in Kaposi's sarcomaassociated herpes virus associated oncogenesis. Semin. Cancer Biol. 18: 423-436.
10. Stoiber H, Pruenster M, Ammann CG, Dierich MP. 2005. Complementopsonized HIV: the free rider on its way to infection. Mol. Immunol. 42:153-160.
11. Ahmad M, Pyaram K, Mullick J, Sahu A. 2007. Viral complement regulators: the expert mimicking swindlers. Indian J. Biochem. Biophys. 44:331-343.
12. Cooper NR. 1998. Complement and viruses, p 393-407. In Volanakis JE, Frank MM (ed), The human complement system in health and disease. Marcel Dekker, Inc, New York, NY.
13. Fleckenstein B, Desrosiers RC. 1982. Herpesvirus saimiri and herpesvirus ateles, p 253-332. In Roizman B (ed), The herpesviruses. Plenum Publishing Corporation, New York, NY.
14. Jung JU, Choi JK, Ensser A, Biesinger B. 1999. Herpesvirus saimiri as a model for gammaherpesvirus oncogenesis. Semin. Cancer Biol. 9:231-239.
15. Jung JU, Desrosiers RC. 1994. Herpesvirus saimiri and ateles, p 614-622. In Webster R, Granoff A (ed), Encyclopedia of virology. Saunders Scientific Publications, Inc, Philadelphia, PA.
16. Falk LA, Wolfe LG, Deinhardt F. 1972. Isolation of herpesvirus saimiri from blood of squirrel monkeys (Saimiri sciureus). J. Natl. Cancer Inst. 48:1499-1505.
17. Albrecht JC, Fleckenstein B. 1992. New member of the multigene family of complement control proteins in herpesvirus saimiri. J. Virol. 66:3937-3940.
18. Fodor WL, Rollins SA, Biancocaron S, Rother RP, Guilmette ER, Burton WV, Albrecht JC, Fleckenstein B, Squinto SP. 1995. The complement control protein homolog of herpesvirus saimiri regulates serum complement by inhibiting C3 convertase activity. J. Virol. 69:3889-3892.
19. Bramley JC, Davies A, Lachmann PJ. 1997. Herpesvirus saimiri CD5-9 baculovirus expression and characterisation of complement inhibitory activity. Biochem. Soc. Trans. 25:354S.
20. Rother RP, Rollins SA, Fodor WL, Albrecht JC, Setter E, Fleckenstein B, Squinto SP. 1994. Inhibition of complement-mediated cytolysis by the terminal complement inhibitor of herpesvirus saimiri. J. Virol. 68:730-737.
21. Singh AK, Mullick J, Bernet J, Sahu A. 2006. Functional characterization of the complement control protein homolog of herpesvirus saimiri: R118 is critical for factor I cofactor activities. J. Biol. Chem. 281:23119-23128.
22. Kohl J. 2006. The role of complement in danger sensing and transmission. Immunol. Res. 34:157-176.
23. Singh AK, Yadav VN, Pyaram K, Mullick J, Sahu A. 2009. Mapping of functional domains in herpesvirus saimiri complement control protein homolog: the complement control protein domain 2 is the smallest structural unit displaying cofactor and decay-accelerating activities. J. Virol. 83:10299-10304.
24. Bernet J, Mullick J, Panse Y, Parab PB, Sahu A. 2004. Kinetic analysis of the interactions between vaccinia virus complement control protein and human complement proteins C3b and C4b. J. Virol. 78:9446-9457.
25. Hammer CH, Wirtz GH, Renfer L, Gresham HD, Tack BF. 1981. Large scale isolation of functionally active components of the human complement system. J. Biol. Chem. 256:3995-4006.
26. Mullick J, Bernet J, Panse Y, Hallihosur S, Singh AK, Sahu A. 2005. Identification of complement regulatory domains in vaccinia virus complement control protein. J. Virol. 79:12382-12393.
27. Pangburn MK. 1987. A fluorimetric assay for native C3. The hemolytically active form of the third component of human complement. J. Immunol. Methods 102:7-14.
28. Sahu A, Isaacs SN, Soulika AM, Lambris JD. 1998. Interaction of vaccinia virus complement control protein with human complement proteins: factor I-mediated degradation of C3b to iC3b1 inactivates the alternative complement pathway. J. Immunol. 160:5596-5604.
29. Arnold K, Bordoli L, Kopp J, Schwede T. 2006. The SWISS-MODEL workspace: a web-based environment for protein structure homology modelling. Bioinformatics 22:195-201.
30. Kiefer F, Arnold K, Kunzli M, Bordoli L, Schwede T. 2009. The SWISSMODEL Repository and associated resources. Nucleic Acids Res. 37: D387-D392. doi:10.1093/nar/gkn750.
31. Peitsch MC. 1995. Protein modeling by e-mail. Biotechnology (NY) 13: 658-660.
32. Pyaram K, Kieslich CA, Yadav VN, Morikis D, Sahu A. 2010. Influence of electrostatics on the complement regulatory functions of kaposica, the complement inhibitor of Kaposi's sarcoma-associated herpesvirus. J. Immunol. 184:1956-1967.
33. Yadav VN, Pyaram K, Mullick J, Sahu A. 2008. Identification of hot spots in the variola virus complement inhibitor (SPICE) for human complement regulation. J. Virol. 82:3283-3294.
34. White J, Lukacik P, Esser D, Steward M, Giddings N, Bright JR, Fritchley SJ, Morgan BP, Lea SM, Smith GP, Smith RA. 2004. Biological activity, membrane-targeting modification, and crystallization of soluble human decay accelerating factor expressed in E. coli. Protein Sci. 13:2406-2415.
35. Kirkitadze MD, Krych M, Uhrin D, Dryden DT, Smith BO, Cooper A, Wang X, Hauhart R, Atkinson JP, Barlow PN. 1999. Independently melting modules and highly structured intermodular junctions within complement receptor type 1. Biochemistry 38:7019-7031.
36. Kuttner-Kondo L, Hourcade DE, Anderson VE, Muqim N, Mitchell L, Soares DC, Barlow PN, Medof ME. 2007. Structure-based mapping of DAF active site residues that accelerate the decay of C3 convertases. J. Biol. Chem. 282:18552-18562.
37. Yadav VN, Pyaram K, Ahmad M, Sahu A. 2012. Species selectivity in poxviral complement regulators is dictated by the charge reversal in the central complement control protein modules. J. Immunol. 189:1431-1439.
38. Pan Q, Ebanks RO, Isenman DE. 2000. Two clusters of acidic amino acids near the NH2 terminus of complement component C4 alpha=-chain are important for C2 binding. J. Immunol. 165:2518-2527.
39. Blom AM, Villoutreix BO, Dahlback B. 2003. Mutations in alpha-chain of C4BP that selectively affect its factor I cofactor function. J. Biol. Chem. 278:43437-43442.
40. Mark L, Lee WH, Spiller OB, Proctor D, Blackbourn DJ, Villoutreix BO, Blom AM. 2004. The Kaposi's sarcoma-associated herpesvirus complement control protein mimics human molecular mechanisms for inhibition of the complement system. J. Biol. Chem. 279:45093-45101.
41. Wu J, Wu YQ, Ricklin D, Janssen BJ, Lambris JD, Gros P. 2009. Structure of complement fragment C3b-factor H and implications for host protection by complement regulators. Nat. Immunol. 10:728-733.
42. Soames CJ, Sim RB. 1997. Interactions between human complement components factor H, factor I and C3b. Biochem. J. 326:553-561.
43. Hourcade D, Liszewski MK, Krych-Goldberg M, Atkinson JP. 2000. Functional domains, structural variations and pathogen interactions of MCP, DAF and CR1. Immunopharmacology 49:103-116.
44. Pangburn MK, Pangburn KL, Koistinen V, Meri S, Sharma AK. 2000. Molecular mechanisms of target recognition in an innate immune system: interactions among factor H, C3b, and target in the alternative pathway of human complement. J. Immunol. 164:4742-4751.
45. Kuttner-Kondo LA, Dybvig MP, Mitchell LM, Muqim N, Atkinson JP, Medof ME, Hourcade DE. 2003. A corresponding tyrosine residue in the C2/factor B type A domain is a hot spot in the decay acceleration of the complement C3 convertases. J. Biol. Chem. 278:52386-52391.
46. Lukacik P, Roversi P, White J, Esser D, Smith GP, Billington J, Williams PA, Rudd PM, Wormald MR, Harvey DJ, Crispin MD, Radcliffe CM, Dwek RA, Evans DJ, Morgan BP, Smith RA, Lea SM. 2004. Complement regulation at the molecular level: the structure of decay-accelerating factor. Proc. Natl. Acad. Sci. U. S. A. 101:1279-1284.
47. Pangburn MK. 1986. Differences between the binding sites of the complement regulatory proteins DAF, CR1, and factorHon C3 convertases. J. Immunol. 136:2216-2221.
48. Liszewski MK, Leung M, Cui W, Subramanian VB, Parkinson J, Barlow PN, Manchester M, Atkinson JP. 2000. Dissecting sites important for complement regulatory activity in membrane cofactor protein (MCP; CD46). J. Biol. Chem. 275:37692-37701.
49. Krych-Goldberg M, Hauhart RE, Subramanian VB, Yurcisin BM, Crimmins DL, Hourcade DE, Atkinson JP. 1999. Decay accelerating activity of complement receptor type 1 (CD35). Two active sites are required for dissociating C5 convertases. J. Biol. Chem. 274:31160-31168.
50. Kostavasili I, Sahu A, Friedman HM, Eisenberg RJ, Cohen GH, Lambris JD. 1997. Mechanism of complement inactivation by glycoprotein C of herpes simplex virus. J. Immunol. 158:1763-1771.
51. Lubinski JM, Wang L, Soulika AM, Burger R, Wetsel RA, Colten H, Cohen GH, Eisenberg RJ, Lambris JD, Friedman HM. 1998. Herpessimplex virus type 1 glycoprotein gC mediates immune evasion in vivo. J. Virol. 72:8257-8263.
52. Kapadia SB, Molina H, Bvan Speck VSH, Virgin HW. 1999. Murine gammaherpesvirus 68 encodes a functional regulator of complement activation. J. Virol. 73:7658-7670.
53. Liszewski MK, Leung MK, Hauhart R, Buller RM, Bertram P, Wang X, Rosengard AM, Kotwal GJ, Atkinson JP. 2006. Structure and regulatory profile of the monkeypox inhibitor of complement: comparison to homologs in vaccinia and variola and evidence for dimer formation. J. Immunol. 176:3725-3734.
54. McKenzie R, Kotwal GJ, Moss B, Hammer CH, Frank MM. 1992. Regulation of complement activity by vaccinia virus complement-control protein. J. Infect. Dis. 166:1245-1250.
55. Mullick J, Bernet J, Singh AK, Lambris JD, Sahu A. 2003. Kaposi's sarcoma-associated herpesvirus (human herpesvirus-8) open reading frame 4 protein (kaposica) is a functional homolog of complement control proteins. J. Virol. 77:3878-3881.
56. Okroj M, Mark L, Stokowska A, Wong SW, Rose N, Blackbourn DJ, Villoutreix BO, Spiller OB, Blom AM. 2009. Characterization of the complement inhibitory function of rhesus rhadinovirus complement control protein (RCP). J. Biol. Chem. 284:505-514.
57. Rosengard AM, Liu Y, Nie Z, Jimenez R. 2002. Variola virus immune evasion design: expression of a highly efficient inhibitor of human complement. Proc. Natl. Acad. Sci. U. S. A. 99:8808-8813.
58. Manuelian T, Hellwage J, Meri S, Caprioli J, Noris M, Heinen S, Jozsi M, Neumann HP, Remuzzi G, Zipfel PF. 2003. Mutations in factor H reduce binding affinity to C3b and heparin and surface attachment to endothelial cells in hemolytic uremic syndrome. J. Clin. Invest. 111:1181-1190.
59. Liszewski MK, Leung MK, Hauhart R, Fang CJ, Bertram P, Atkinson JP. 2009. Smallpox inhibitor of complement enzymes (SPICE): dissecting functional sites and abrogating activity. J. Immunol. 183:3150-3159.
60. Liszewski MK, Leung MK, Atkinson JP. 1998. Membrane cofactor protein: importance of N- and O-glycosylation for complement regulatory function. J. Immunol. 161:3711-3718.
61. Mullick J, Singh AK, Panse Y, Yadav V, Bernet J, Sahu A. 2005. Identification of functional domains in kaposica, the complement control protein homolog of Kaposi's sarcoma-associated herpesvirus (human herpesvirus-8). J. Virol. 79:5850-5856.
62. Krych M, Clemenza L, Howdeshell D, Hauhart R, Hourcade D, Atkinson JP. 1994. Analysis of the functional domains of complement receptor type 1 (C3b/C4b receptor, CD35) by substitution mutagenesis. J. Biol. Chem. 269:13273-13278.
63. Saunders RE, Goodship TH, Zipfel PF, Perkins SJ. 2006. An interactive web database of factor H-associated hemolytic uremic syndrome mutations: insights into the structural consequences of disease-associated mutations. Hum. Mutat. 27:21-30.
64. Xu H, Kitano E, Sato Y, Kobayashi C, Firdawes S, Kitamura H, Fukuzawa M, Miyagawa S. 2008. Studies of monkey complement: measurement of cynomolgus monkey CH50, ACH50, C4, C2 and C3. Xenotransplantation 15:14-19.